Papillary Adenocarcinoma — Trials

Papillary Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 48
Recruiting: 19
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 1–25 of 25 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04071223	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study	active not recruiting	Phase 2	98	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT03635892	A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma	active not recruiting	Phase 2	60	Memorial Sloan Kettering Cancer CenterOTHER	1